Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 5th 2019

Detecting MRD During and After Hematopoietic Stem Cell Transplantation

Laura Joszt, MA

Two abstracts presented at the Transplantation and Cellular Therapy Meetings analyzed the detection of minimal residual disease during and after hematopoietic stem cell transplantation.

March 2nd 2019

Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds

Laura Joszt, MA

Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.

March 2nd 2019

Biologic Age Associated With Breast Cancer Risk

Samantha DiGrande

Scientists at the National Institutes of Health have recently found that biologic age, or a DNA-based estimate of a person’s age, is associated with future development of breast cancer.

March 1st 2019

Improving Patient-Reported Measurement in Oncology Value-Based Care

Allison Inserro

How to improve patient-reported measurement in oncology valued-based care is the focus of a new report from The National Pharmaceutical Council and Discern Health.

February 28th 2019

What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue

AJMC Staff

Researchers have confirmed that there is no link between flu shots and miscarriages; a liquid biopsy is as effective as tissue-based testing for identifying treatment for lung cancer; and physicians generate an average of $2 million a year for hospitals.

February 27th 2019

Mergers, New Locations for Care, and the Oncologist

Bruce Feinberg, DO, vice president and chief medical officer for Cardinal Health Specialty Solutions, recently chaired a discussion centered on the flurry of megamergers in healthcare: Walmart and Humana, Aetna and CVS, Cigna and Express Scripts, and Amazon and PillPack.

February 27th 2019

Improving Oncology Practices With Value-Based Care

On March 7, The American Journal of Managed Care® will host its latest Institute for Value-Based Medicine in Dallas, Texas, with the Advancing Quality Oncology Care in the Evolving Value-Based Care Landscape meeting.

February 26th 2019

Using NGS to Assess Minimal Residual Disease Better Predicts Outcomes in AML

Laura Joszt, MA

A high proportion of patients with acute myeloid leukemia (AML) who achieve a negative minimal residual disease (MRD) status still relapse, indicating a more sensitive method of detecting MRD is needed.

February 26th 2019

Therapeutics

Christina Mattina Mary Caffrey

Therapeutic updates from Patient-Centered Oncology Care® 2018.

February 26th 2019

Reporting and Design

Mary Caffrey Jaime Rosenberg

Updates on reporting otucomes and pathway design from Patient-Centered Oncology Care®.

February 25th 2019

Looking Ahead

Christina Mattina Mary Caffrey

Various stakeholders discuss the future of oncology care at the Patient-Centered Oncology Care® meeting. Editor’s Note: After this issue went to press, Wes Hall passed away February 20, 2019, after living more than 5 years with stage IV stomach cancer. He was active in the Community Oncology Alliance Patient Advocacy Network and supported participation in clinical trials.

February 25th 2019

Keynote Speaker: AMA's McAneny Calls for Real-time Oncology Payment Model Led by Physicians

Mary Caffrey

The major alternative payment model put forth by Medicare, the Oncology Care Model, doesn’t tell practices how they are doing until after the fact. This puts practices at risk for things beyond their control, said Barbara McAneny, MD, a New Mexico oncologist/hematologist who is the current president of the American Medical Association (AMA).

February 24th 2019

Podcast: This Week in Managed Care—CAR T Therapy Coverage and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 22nd 2019

PET Scans Could Identify Patients With Breast Cancer Who May Be Able to Avoid Chemotherapy

Laura Joszt, MA

Researchers have used positron emission tomography scans to identify which patients with a type of human epidermal growth factor receptor 2–positive breast cancer might benefit most from targeted agents alone and can be spared chemotherapy.

February 20th 2019

Pursuing Eradication of Cervical Cancer Through Preventive Interventions

Wallace Stephens

The majority of countries could see an end to cervical cancer as a public health problem by 2060, according to a new study in The Lancet Oncology.

February 19th 2019

Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer

Mary Caffrey

The update follows a study published in November that found almost no difference in the frequency of mutations between patients with breast cancer who met National Comprehensive Cancer Network guidelines and those who didn't.

February 19th 2019

Humanistic and Economic Burden of Hepatocellular Carcinoma: Systematic Literature Review

Christine G. Kohn, PharmD Prianka Singh, PharmD, MPH Beata Korytowsky, MA Jonathan T. Caranfa, PharmD Jeffrey D. Miller, MS Bruce E. Sill, PharmD, MS Alexander C. Marshall, PharmD, MPH Neehar D. Parikh, MD, MS

Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.

February 17th 2019

Podcast: This Week in Managed Care—Contraceptive Demand and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

February 16th 2019

Dr Thomas Martin Outlines How MRD Testing Is Being Used

Currently, minimal residual disease testing is being used for prognostication not for treatment decisions, explained Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.

February 15th 2019

AJMCtv® Interviews, February 2019

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

February 15th 2019

This Week in Managed Care: February 15, 2019

This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.

$Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab$

February 15th 2019

Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab

Laura Joszt, MA

Minimal residual disease (MRD) is a strong prognosticator of cancer outcomes, and recent research found that patients with relapsed/refractory multiple myeloma (MM) are more likely to achieve MRD on daratumumab than on a standard of care alone.

February 14th 2019

EBO February 2019 Medical World News: Regulatory Updates

Kelly Davio Jaime Rosenberg Laura Joszt, MA Samantha DiGrande

February 14th 2019

Medical World News: Clinical Updates

Kelly Davio Jaime Rosenberg Samantha DiGrande Laura Joszt, MA

February 14th 2019

Moving Toward the "Tipping Point" for Transformation in Cancer Care

Mary Caffrey

Andrew Pecora, MD, FACP, CPE, recently visited Evidence-Based OncologyTM to discuss the progress of COTA’s, a company created in 2011 to develop technology that Pecora said is poised to transform cancer care delivery by helping oncologists and other specialists make decisions that will yield the best outcomes in the most cost-effective way, all at the point of care.

February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Mary Caffrey

Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.

February 13th 2019

What We're Reading: Pediatric Mental Health Care; Brain Cancer Immunotherapy; Preventing Perinatal Depression

AJMC Staff

Half of children in with treatable mental health disorders in the United States do not get treatment; a small study demonstrated benefit with immunotherapy for glioblastoma; a task force recommends counseling services for new mothers at risk of depression.

February 13th 2019

Despite Being Involved in Cancer Treatment Decisions, PCPs Lack Knowledge, Confidence

Jaime Rosenberg

While one-third of primary care providers (PCPs) reported participating in breast cancer treatment decisions with their patients, a significant amount of them also indicated that they were not comfortable or did not feel that they had the necessary knowledge to participate in the treatment decision-making process.

February 13th 2019

Is Immunotherapy the Future of Glioblastoma Treatment?

Samantha DiGrande

Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.

February 12th 2019

Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options

Mary Caffrey

From her vantage point at Rutgers Cancer Institute of New Jersey, Janice Mehnert, MD, has had a front-row seat to the immuno-oncology revolution. Mehnert returned to her alma mater in 2007, and since 2014, she has headed Rutgers’ Phase I/ Developmental Therapeutics Program; she is also head of the melanoma research team. Her work on the KEYNOTE-028 trial has produced important results in multiple cancers, including neuroendocrine tumors, thyroid cancer, small cell lung cancer, and, recently, advanced ovarian cancer.

...

28 29 30 31 32 33 34 35 36

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions